Bionano Genomics (BNGO) Non-Current Deffered Revenue (2017 - 2026)

Bionano Genomics has disclosed Non-Current Deffered Revenue across 10 years of filings, most recently posting $143000.0 for Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $143000.0, down 51.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $143000.0 (down 51.03% YoY), and the FY2025 annual result was $249000.0, down 6.74% from the prior year.
• Non-Current Deffered Revenue came in at $143000.0 for Q1 2026 at Bionano Genomics, down from $249000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $292000.0 in Q1 2025 to a low of $127000.0 in Q4 2022.
• The 5-year median for Non-Current Deffered Revenue is $192000.0 (2025), against an average of $196647.1.
• Across the five-year window, Non-Current Deffered Revenue soared 111.59% in 2025 and tumbled 51.03% in 2026, its largest moves.
• Bionano Genomics' Non-Current Deffered Revenue stood at $127000.0 in 2022, then increased by 21.26% to $154000.0 in 2023, then jumped by 73.38% to $267000.0 in 2024, then declined by 6.74% to $249000.0 in 2025, then tumbled by 42.57% to $143000.0 in 2026.
• The last three Non-Current Deffered Revenue figures came in at $143000.0 (Q1 2026), $249000.0 (Q4 2025), and $192000.0 (Q3 2025), per Business Quant data.